Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New RSV shot shows promise for vulnerable babies

NCT ID NCT06042049

First seen Apr 26, 2026 · Last updated May 22, 2026 · Updated 5 times

Summary

This study tested a medicine called nirsevimab in 33 Japanese infants under 1 year old who are at high risk for severe RSV infection due to heart or lung problems, weak immune systems, Down syndrome, or premature birth. The goal was to check safety and how the body responds to two doses given 5 to 6 months apart. The study found that the treatment was generally safe and helped produce antibodies against RSV.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RESPIRATORY SYNCYTIAL VIRUS INFECTIONS are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Research Site

    Bunkyō City, 113-8519, Japan

  • Research Site

    Fuchu-shi, 183-8561, Japan

  • Research Site

    Fukuoka, 813-0017, Japan

  • Research Site

    Kitakyusyu-shi, 806-8501, Japan

  • Research Site

    Kōtoku, 135-8577, Japan

  • Research Site

    Kurume-shi, 830-0011, Japan

  • Research Site

    Nagasaki, 852-8501, Japan

  • Research Site

    Saitama-shi, 336-8522, Japan

  • Research Site

    Yokohama, 232 8555, Japan

Conditions

Explore the condition pages connected to this study.